 |
|
oral Hsp90 inhibitor IPI-493
An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or "client" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | heat shock protein 90 inhibitor IPI-493 | | | | Code name: | | IPI-493 | | |
|
|
